MedTrace Logo

Evaluate the Effectiveness and Safety of DPCP Ointment (Samcyprone™) on the Clearance of Verruca Vulgaris (Common Warts)

NCT02640820 · Status: UNKNOWN · Phase: PHASE2 · Type: INTERVENTIONAL · Enrollment: 83

Last updated 2018-02-23

No results posted yet for this study

Summary

Warts are benign epidermal tumors caused by human papillomaviruses (HPVs). The active pharmaceutical ingredient DPCP has been used for many years as a compounded formulation in acetone for the treatment of warts, alopecia areata and more recently, cutaneous metastatic melanoma lesions. An improved topical ointment formulation of DPCP called Samcyprone™ will be evaluated for the treatment of common warts.

Conditions

  • Common Warts
  • HPV (Human Papillomavirus)
  • Periungual Warts
  • Plantar Warts

Interventions

DRUG

Sensitizing DPCP Ointment

Sensitization

DRUG

Treatment DPCP Ointment

Treatment

Sponsors & Collaborators

  • RXi Pharmaceuticals, Corp.

    lead INDUSTRY

Principal Investigators

  • Pamela Pavco, PhD · RXi Pharmaceuticals

Study Design

Allocation
NON_RANDOMIZED
Purpose
TREATMENT
Masking
NONE
Model
SINGLE_GROUP

Eligibility

Min Age
18 Years
Max Age
65 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2015-12-31
Primary Completion
2018-01-31
Completion
2018-05-31

Countries

  • United States

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT02640820 on ClinicalTrials.gov